Presentations

Documents

Order by : Name | Date | Hits | [ Descendent ]

Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a... Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a...

hot!
Date added: 08/06/2018
Date modified: 08/06/2018
Filesize: 1.91 MB
Downloads: 986

"Disruption of hepatic IL-1 signaling improves insulin sensitivity and hepatic inflammation in a model of non-alcoholic fatty liver disease (NAFLD)"

Poster presentation given by UMC at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington DC, USA, 20th - 24th October 2017

Mechanisms of Fibrogenesis in NASH Mechanisms of Fibrogenesis in NASH

hot!
Date added: 04/11/2019
Date modified: 04/11/2019
Filesize: 6.53 MB
Downloads: 995

Oral presentation given by UMC at the EASL NAFLD Summit, Geneva, Switzerland, 21st September 2018

The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in... The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in...

hot!
Date added: 01/19/2019
Date modified: 01/19/2019
Filesize: 2.69 MB
Downloads: 999

"The vanin 1-cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease"

Poster presentation given by UNEW at the EASL International Liver Congress, Paris, France, 11th - 15th April 2018

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease

hot!
Date added: 01/03/2018
Date modified: 01/03/2018
Filesize: 17.71 MB
Downloads: 1014

Oral presentation given by UNEW at the Falk Forum 56, Coventry, UK, 3rd February 2017

A mouse model with inducible ablation of TGFβ receptor type 2 limited to hepatic stellate cells... A mouse model with inducible ablation of TGFβ receptor type 2 limited to hepatic stellate cells...

hot!
Date added: 08/06/2018
Date modified: 08/06/2018
Filesize: 1.52 MB
Downloads: 1021

"A mouse model with inducible ablation of TGFβ receptor type 2 limited to hepatic stellate cells predicts the power of HSC-specific TGFβ pathway inhibition"

Poster presentation given by UMC at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington DC, USA, 20th - 24th October 2017

Dietary counselling focusing only on fructose consumption improves hepatic inflammation in... Dietary counselling focusing only on fructose consumption improves hepatic inflammation in...

hot!
Date added: 08/06/2018
Date modified: 08/06/2018
Filesize: 1.94 MB
Downloads: 1043

"Dietary counselling focusing only on fructose consumption improves hepatic inflammation in patients with NAFLD - a prospective, controlled, randomized open-label study (NUCES NASH)"

Poster presentation given by UMC at the 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington DC, USA, 20th - 24th October 2017

Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?

hot!
Date added: 11/01/2018
Date modified: 11/01/2018
Filesize: 9.2 MB
Downloads: 1063

Oral presentation given by CNR at the 10th Serbian Congress on Diabetes, Belgrade, Serbia, 20th November 2017

Lifestyle intervention in NASH - Backbone of therapy or ineffective? Lifestyle intervention in NASH - Backbone of therapy or ineffective?

hot!
Date added: 11/01/2018
Date modified: 11/01/2018
Filesize: 2.17 MB
Downloads: 1075

Oral presentation given by UMC at the Global NASH Congress, London, UK, 26th February 2018

P465L PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates P465L PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates

hot!
Date added: 07/28/2018
Date modified: 07/28/2018
Filesize: 1.42 MB
Downloads: 1086

Poster presentation given by UCAM at the Conference: “Metabolism in Action - Lifetime influence of genes and environment”, organized by the Copenhagen Bioscience Conferences, a Novo Nordisk Foundation initiative, Hillerød, Denmark, 1st - 5th October 2017

Which patients will we be treating in 2020 and how will pharmacotherapy be tailored? Which patients will we be treating in 2020 and how will pharmacotherapy be tailored?

hot!
Date added: 01/19/2019
Date modified: 01/19/2019
Filesize: 4.98 MB
Downloads: 1092

Oral presentation given by UNITO at the EASL International Liver Congress, Paris, France, 11th - 15th April 2018